MEI Pharma - MEIP Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings or view top-rated stocks.

5 analysts have issued twelve-month price targets for MEI Pharma's stock. Their MEIP share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts.

MEI Pharma's stock was trading at $0.2436 at the start of the year. Since then, MEIP shares have decreased by 1.5% and is now trading at $0.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023.
View our MEIP earnings forecast.

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings data on Thursday, February, 9th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.24. The business had revenue of $32.74 million for the quarter, compared to analyst estimates of $9.69 million. MEI Pharma had a negative net margin of 49.80% and a negative trailing twelve-month return on equity of 88.33%.

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.00%), Millennium Management LLC (0.26%), Wells Fargo & Company MN (0.20%), Morgan Stanley (0.14%), Two Sigma Investments LP (0.14%) and UBS Group AG (0.10%). Insiders that own company stock include Charles V Baltic III and Frederick W Driscoll.
View institutional ownership trends.

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEIP stock can currently be purchased for approximately $0.24.

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $31.98 million and generates $40.70 million in revenue each year. The company earns $-54,450,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.